NEW CHALLENGES FOR HIV INFECTION

New targets and new drugs in the treatment of HIV

José López-Aldeguer1, Koldo Aguirrebengoa2, José Ramón Arribas3 and José María Kindelán3

1Hospital Universitario La Fe, Valencia, España; 2Hospital de Cruces, Bilbao, España; 3Hospital Universitario La Paz, Madrid, España.

Palabras clave: VIH. Agentes anti-VIH. Inhibidores de la transcriptasa inversa del VIH-1. Inhibidores de la proteasa.

Antiretroviral treatment has modified the course of human immunodeficiency virus (HIV) infection transforming it into a chronic disease. However, as treatment is conceived “for life”, more effective and safety drugs, overcoming the growing resistance of the virus are required. New molecules may block the known viral targets or other new ones.

The mechanism of the virus union and entrance to the cell includes the new therapeutic targets that are studied more frequently. Although studies with substances that efficiently block the virus-CD4 receptors union are in very early phases, other studies of molecules capable to block the entrance co-receptors are in more advanced phases (II or III), and enfuvirtide, a substance that blocks membrane fusion, the last phase of virus entrance, has been recently marketed. Another very promising pharmacological target is the integration of the proviral DNA as we know some substances that in vitro block HIV integrase.

Besides this, new drugs are increasing the three classic antiretroviral families. Among nucleoside analogs emtricitabine (recently marketed) and amdoxovir are the more prominent. Capravirine and TMC-125 are the non-nucleoside analogs whose studies are more advanced. And atazanavir, fos-amprenavir, tipranavir and TMC-114 are the new protease inhibitors recently marketed or near to be.

Key words: HIV. Anti-HIV agents. HIV-1 reverse transcriptase inhibitors. HIV protease inhibitors. HIV fusion inhibitors. HIV-1 integrase inhibitors.

Introduction

The acquired immune deficiency syndrome is currently one of the main causes of mortality in the world. Antiretroviral therapy reduces viral replication and disease progression, with the result that mortality has fallen in countries which have access to therapy. Nevertheless, currently available drugs cannot eradicate the virus and therapy is considered as being “for life”. Prolonged treatments and their difficult follow-up (poor adhesion), have brought to light problems which were originally expected such as resistance to antiretrovirals, unexpected adverse effects (e.g. mitochondrial toxicity), redistribution of body fat and metabolic alterations which can lead to secondary diseases. The prevalence of primary or acquired resistance to avail-
of the viral surface. The binding site of the virus to the CD4 receptor is formed by specific regions of gp120 which use the primary sequence and their spatial conformation to create a domain which is capable of recognizing its target (CD4 receptor) and binding to this with greater of lesser affinity according to the existence or not of mutations in glycoprotein gp120 or in the CD4 receptor. From the pathophysiologic viewpoint, we can consider three phases, or mechanisms, of viral entry to the cell and each can be a therapeutic target: a) adhesion of the virus to the CD4 receptor, b) binding of chemokines to the receptors which act as HIV co-receptors, and c) fusion of viral and cell membranes.

**Binding of the virus to the CD4 receptor**

This step is mediated by gp120 and the domain which recognizes the CD4 receptor. The appearance of gp120 is that of a spike (trimer) formed by different loops (V1-V5) and in which the binding region has been described in the conserved part of the V1-V2 trunk and near V3. Some biological activities of the virus such as cellular tropism, pathogenicity, capacity for fusion and use of co-receptors, seem to be mediated by a domain in the V3 loop. After binding of gp120 to the CD4 receptor, conformational changes are introduced which bring the virus closer to the chemokine receptors.

**Binding to co-receptors**

Changes in the conformation of gp120 reveal the epitopes required for binding to chemokine receptors. Chemokines are small proteins with a pro-inflammatory function released by macrophages, activated T lymphocytes and other mononuclear cells (in the case of MIP-1α, MIP-1β and RANTES) or produced by stromal cells (in the case of SDF-1) which, when bound to their receptors, transmit a signal to the inside of the cell by activating chemotaxis. Most chemokines can be grouped according to a sequence of amino acids which is characteristic in two families: CC and CXC. The production of chemokines and the availability of their receptors depend on several factors, such as the presence of cytokines, infections by microorganisms, etc.

The chemokine receptors used by retroviruses to enter the cell are the true HIV receptors, as some genetically modified HIV strains have been observed to be capable of entering the cell without using the CD4 receptor. The CCR5 receptor of the β-chemokine has been identified as a co-receptor of the recently infected viruses, with a tropism for macrophages with this receptor in their membrane and with little capacity to form syncytes in lymphoid cell lines. The virus used by this receptor is known as HIV-Δ. The importance of the CCR5 receptor during the initial moments of infection can be evaluated by the fact that people lacking it (those who are homozygotic for the deletion of 32 base pairs in the CCR5 gene known as polymorphism Δ32) are resistant to infection by HIV-Δ, and in heterozygotes, the infection progresses more slowly. Nevertheless, these people can be infected by the CXCR4 receptor, although this is very rare. Furthermore, viruses using the CXCR4 co-receptor (virus R4) infect both macrophages and lymphocytes, are more common in advanced stages of infection and have a high cytolitic and syncytia-forming capacity.

**Drugs which act on new targets**

**HIV binding and penetration of the cell**

The human immunodeficiency virus (HIV) is covered by a double-lipid layer speckled with viral glycoproteins of which the most important are gp120 and gp41. These are related and stem from a larger common precursor: gp160. gp120 stems from the terminal amino portion of gp160 and is situated at the most external part of the viral lipid layer; this glycoprotein intervenes in the binding of the CD4 receptor and “directs” the fusion mechanism, gp41 stems from the C-terminal portion of gp160; it is a transmembrane protein and plays an important role in membrane fusion. The infectivity of a virus requires the presence of both glycoproteins.

The amino acid sequence of gp120 is formed by five variable regions (V1 to V5), which alternate with more conserved regions. The variable regions are the most exposed
Fusion of the cell and viral membranes

Fusion of both membranes is the last step in the mechanism of viral entry into the cell and is mediated by gp41. This is a transmembrane glycoprotein whose most distal portion, the aminoterminal portion, contains a glycine-rich hydrophobic radical (where the fusion peptide is formed) which is essential for binding of the membranes. Between the N-terminal and C-terminal portions of gp41 there are two helicoidal structures, or heptad repeats (HR), each identified as HR-1 and HR-2. HR-1 is distal to the virus and closer to the fusion peptide. In the free virion, gp41 has a non-fusogenic conformation, but when gp120 binds to its receptor, gp41 undergoes a conformational change and an elongation (pre-intermediate hairpin) is formed which inserts the fusion peptide into the target cell membrane. After insertion, HR-2 folds into three helicoids on the three HR-1 helicoids, forming a six-helix structure whose objective is to further reduce the distance between the virus and the cell until it brings both membranes into contact so that they finish by merging.

Blocking entry of the virus

The drugs which act on any of three steps mentioned above can block entry of the virus to the cell. Its targets can be any of the two glycoproteins of the virus (gp120 and gp41) or their corresponding cellular receptors or co-receptors. The number of substances with this capacity now being studied is very high, most are in early phases of investigation and very few are likely to be used in clinical practice (table 1). Nevertheless, a drug is available (T-20, enfuvirtide or Fuzeon®) whose role as a component of antiretroviral therapy is being defined.

Inhibitors of HIV binding to CD4

Non-specific inhibitors

Polyanionic molecules. Certain sulphated polysaccharides (dextran-sulphate, pentoan-sulphate or heparin) can inhibit viral replication in vitro. The anti-HIV activity of compounds with structures which are so heterogeneous seems to be due to the fact that they have a high density of negative charges (polyanions). Dextran-sulphate binds to the V3 loop of gp120 in CXCR4 strains and prevents binding to the CD4 receptor. Other substances which share this mechanism of action are PRO 2000 and cyanovirin-N. Although they are unlikely to be used in clinical practice, different polyanions are currently being evaluated as topical agents8.

Specific inhibitors

Soluble recombinant CD4 (srCD4). srCD4 was one of the first antiretroviral drugs to be studied. It acts by blocking gp120 and has proven to very active in vitro. Nevertheless, its activity is much lower against viral strains from patients, possibly because there are viral variants of lower affinity. Therefore, srCD4 has not been developed as an anti-HIV agent5,6.

Membrane fusion inhibitors

Enfuvirtide (T-20). Peptide interferes with gp41-mediated fusion. Clinical use SC Activity maintained for 48 weeks in rescue therapy

T-1249 Peptide, interferes with gp41-mediated fusion Phase 2 SC Activity against T-20-resistant strains (development stopped)

<table>
<thead>
<tr>
<th>Type of inhibitor</th>
<th>Mechanism of action</th>
<th>Phase of development</th>
<th>Route of administration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4-specific inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rsCD4</td>
<td>Competitive binding with glycoprotein gp120</td>
<td>Phase 1-2</td>
<td>IV</td>
<td>Limited activity; development abandoned</td>
</tr>
<tr>
<td>TNX-355</td>
<td>Anti-CD4 monoclonal antibody; prevents binding of virus to chemokine receptor</td>
<td>Phase 1-2</td>
<td>IV</td>
<td>Demonstrated dose-dependent activity</td>
</tr>
<tr>
<td>TRO-542</td>
<td>CD4 tetramer bound to a gammaglobulin</td>
<td>Phase 1-2</td>
<td>IV</td>
<td>Preliminary activity data; YM &gt; 72 h</td>
</tr>
<tr>
<td>S-2006</td>
<td>Binding to gp120 by blocking CD4 binding</td>
<td>Preclinical</td>
<td></td>
<td>Rapid induction of resistance</td>
</tr>
<tr>
<td>Non-specific inhibitors of gp120-CD4 binding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dextran sulphate</td>
<td>Eletrostatic binding to gp120; inhibits interaction with CXCR4</td>
<td>Phase 1-2</td>
<td>IV</td>
<td>Moderate activity; high toxicity</td>
</tr>
<tr>
<td>PRO 2000</td>
<td>Binding to CD4; interferes with binding to gp120</td>
<td>Phase 2</td>
<td>Topical</td>
<td>Being studied in Africa</td>
</tr>
<tr>
<td>Cyanovirin-N</td>
<td>Binding to gp120, interferes with CD4- CXCR4 interaction</td>
<td>Preclinical</td>
<td>Topical</td>
<td>Protein structure</td>
</tr>
<tr>
<td>Chemokine receptor inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCH-D</td>
<td>RANTES antagonist, competitive binding to CCR5</td>
<td>Phase 1-2</td>
<td>Oral</td>
<td>Dose-dependent activity; mutation strains R5 to X4</td>
</tr>
<tr>
<td>PRO 140</td>
<td>Anti CCR5 monoclonal antibody</td>
<td>Preclinical</td>
<td></td>
<td>Potency (1.8 log UV reduction)</td>
</tr>
<tr>
<td>UK 427</td>
<td>Anti-CCR5 activity</td>
<td>Phase 2-3</td>
<td>Advanced development</td>
<td></td>
</tr>
<tr>
<td>AMD3100</td>
<td>“Bicyclam” CXCR4 inhibitor</td>
<td>Phase 2</td>
<td>IV</td>
<td>Low potency</td>
</tr>
<tr>
<td>Membrane fusion inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enfuvirtide (T-20)</td>
<td>Peptide interferes with gp41-mediated fusion</td>
<td>Clinical use</td>
<td>SC</td>
<td>Activity maintained for 48 weeks in rescue therapy</td>
</tr>
<tr>
<td>T-1249</td>
<td>Peptide, interferes with gp41-mediated fusion</td>
<td>Phase 2</td>
<td>SC</td>
<td>Activity against T-20-resistant strains (development stopped)</td>
</tr>
</tbody>
</table>
Anti-CD4 monoclonal antibodies. These are monoclonal antibodies anti determined epitopes of the CD4 receptor or of gp120 which, on binding, block interaction and repress the replication of several viral sub-types. Even though blockade of the CD4 receptors could lead to some degree immunosuppression, at least the so-called TNX-355 antibody has been well tolerated and CD4+ lymphocytopenia has not been reported. A first clinical trial (phase I/II) at a single dose of TNX-355 showed a reduction in viral load and an increase in CD4+ cells at 21 days. Nevertheless, longer clinical trials are necessary to confirm the usefulness of this antibody. PRO-542 is a hybrid tetramer which contains domains of the CD4 receptor bound to IgG, and which acts as a decoy of the CD4 receptor to which viral gp120 binds, thus preventing its binding to the real CD4 receptor. In vitro, it has shown activity with both laboratory and clinical strains, and this activity has been confirmed in vivo in a small number of advanced-stage patients.

BMS-806. This substance forms part of other molecules which can bind competitively and reversibly to gp120 by blocking the interaction with the CD4 receptor. It has been evaluated in vitro and is active against different strains of HIV, although the early emergence of mutation-related resistance at the point of action of gp120 leads it to lose efficacy.

Substances which block binding to chemokine receptors

The discovery of co-receptors for entry of the virus has opened up new possibilities in the development of anti-HIV drugs. Attempts have been made to emulate the structure of the natural cytokines which block these receptors and inhibit viral replication. Early-stage studies are being conducted on drugs which block one or the other co-receptor, with doubts as to whether blockade can induce mutations in the strain, thus making it easy for the virus to use the other receptor.

CCR5 receptor antagonists

Tak-220. Preclinical studies of this molecule have shown high specificity for CCR5 with no affinity for other ligands. Similarly, oral administration enables suitable levels of the drug in blood to be reached.

SCH-C/SCH-D. These substances have a high intrinsic activity against B5 strains and are synergic with other antiretroviral drugs. SCH-C has undergone a phase I/Ii trial in 12 patients for 10 days and has shown a reduction in viral load of between 0.5 and 1.0 log. Nevertheless, its development has been stopped because of the risk of cardiac arrhythmias after reports of a lengthening of the QT interval. It has been replaced by SCH-D, which has recently been reported to be more potent (mean reduction in viral load of 1.5 log), is better tolerated and has no effect on heart rate. Nevertheless, it is important to note that one of the 48 patients studied developed a mixed viral strain, B5/X4 and another developed an X4 strain on finishing therapy.

UK-427,857. This drug is active against a wide number of viral strains and is specific for the CCR5 receptor (not active against CXCR4 strains). It is currently in phase II/III studies.

Other substances. Other substances in early stages are Pro-140, which is a specific and potent monoclonal antibody (reduction in viral load to 1.0 log), can inhibit entry of the virus and does not block CCR4 receptor activity. GW871140 has shown good tolerance (digestive symptoms) and a prolonged half-life after oral administration. AMD887 is active and potent in vitro, both as the only drug and in combination with AMD700 (CXCR4 co-receptor inhibitor).

CXCR4 receptor antagonists

Bicyclams. These molecules are so named because they are composed of two macrocyclical rings (cyclams) bound by an aliphatic or aromatic chain. They are very potent and are active against HIV-1 and HIV-2 in cell culture, but have been ruled out as drugs in clinical trials. More information is available for AMD3100. In vitro studies in which peripheral mononucleated cells infected with strains X4 and B5 were placed into contact with AMD3100 revealed blockade of the CXCR4 receptor and they were only collected in the B5 virus supernatant. In another study with peripheral blood lymphocytes infected by syncytium-forming viruses, these strains lost their capacity to form syncytia by mutating to use the CCR5 co-receptor. This mutation can shorten the course of the disease. Nevertheless, the development of AMD3100 has been stopped because of the adverse effects observed in a phase I study, although other compounds, such as AMD700, are being studied, and have shown in vitro activity against a large number of strains which are resistant to several current used drugs.

KRH-1636 and KRH-2731 are potent antagonists of the CXCR4 receptor, can be administered orally and are active in pre-clinical studies.

Blockade of viral fusion with the cell membrane

Substances which are currently known to block fusion of the viral capsid and cell membrane are synthetic peptides which camouflages the HR-2 region of gp41. They act on the attack hairpin by inhibiting its formation. This attack hairpin is necessary for fusion of the virus. One of the most important of these substances is enfuvirtide (T-20) and T-1249.

Enfuvirtide is a 36-aminoacid peptide which camouflages a sequence of the HR-2 region and is active against strains X4 and B5. It binds to the HR-1 domain of the gp41 virus by preventing the formation of the 6-helix structure necessary to start the conformational changes which finish in membrane fusion. The drug is active during the phase where the virus approaches the target cell in which gp41, and specifically the HR-1 domain, are accessible. This “therapeutic window” can vary according to the affinity of the virus for the receptor, in such a way that, if affinity is very high, the drug can act more quickly and its efficacy is lower in these viral strains. The efficacy of enfuvirtide is not modified independently of the co-receptor used by the virus.

Enfuvirtide is marketed in many countries. Initial studies using the drug in intravenous monotherapy showed a potent antiretroviral effect with few adverse effects. This
activity was proven both for sub-type B (dominant in Eu-
rope and the USA) and against other viral sub-types. The
optimal subcutaneous dose was initially determined in a
continuous perfusion pump and later in two daily doses in
16 adults who achieved a negative viral load (< 500 cop/ml)
when the dose was above 100 mg. Studies in vitro have
shown the synergy of enfuvirtide with other binding block-
ers such as AMD-3100, SCH-C and PRO-54229.

The results of two parallel studies (TORO-1 and
TORO-2) which included 995 very experienced patients
have been essential in allowing health authorities to ap-
prove this drug in clinical practice. These trials compared
the response to the best treatment possible (three to five
drugs) determined using genotypic and phenotypic resis-
tance studies, by adding enfuvirtide to a group of the
study subjects (proportion 2:1). At 24 and 48 weeks, both
the reduction in viral load and the increase in CD4+ lym-
phocytes were higher in the group which combined with
enfuvirtide. The median time to virological failure (taking
into account that the trial involved multi-treated patients)
improved from 11 to 32 weeks26-28 (fig. 2). The adverse
effects were similar in both groups except for local reactions at the injection point. Global incidence
of bacterial disease was similar in both groups, but in
the enfuvirtide treated group, a greater incidence of
pneumonia was observed, with no apparent cause. As far
as laboratory alterations were concerned, there were re-
ports of an increase in peripheral eosinophilia in the en-
fvirtide arm, although cases of hypersensitivity are
rare. The injection site reaction involved painful inflam-
atory nodules which occurred in most patients and last-
ed from one to three days. Only a small number of pa-
tients modified their daily activities or needed pain
killers for the nodules, although 2.8% stopped treatment
for this reason29.

The efficacy of enfuvirtide in monotherapy is transito-
ry, therefore it must be combined with other antitretrovi-
rals to which the virus is susceptible. Resistance to enfu-
virtide is related to mutations in the gp41 gene. The
HR-1 and HR-2 domains are relatively stable, but the re-
ported cases of resistance are related to mutations in
codons 36 to 45 of gp41 with a variable reduction in sus-
ceptibility of between 9.1 and 45 times. The viruses which
present this mutation have reduced fitness30.

Enfuvirtide is indicated in HIV+ patients who have
failed with regimens of at least one drug from the three
groups of antiretrovirals or who have developed inter-
ference to previous therapy. Given that the TORO studies
showed a better virological response if enfuvirtide is com-
bined with active drugs, the drug must be administered
before patients have run out of therapeutic options.

T-1249. This is a second-generation fusion inhibitor
It is a 39-aminoacid peptide designed from different
HR-2 regions of HIV-1, HIV-2 and SIV. As with enfuvir-
tide, T-1249 has a high capacity for reducing viral repli-
cation in HIV strains which are multi-resistant to current
drugs, even those which are resistant to T-20, and in sub-
types A to C in naïve patients and those on monother-
apy. T-1249 has proven to be very potent at a single
daily dose (fall in viral load of 2.0 log3,31). Nevertheless, the
clinical development program of this product has been tem-
porarily stopped because of technical difficulties.

The efficacy of enfuvirtide in monotherapy is transito-
ry, therefore it must be combined with other antitretrovi-
rals to which the virus is susceptible. Resistance to enfu-
virtide is related to mutations in the gp41 gene. The
HR-1 and HR-2 domains are relatively stable, but the re-
ported cases of resistance are related to mutations in
codons 36 to 45 of gp41 with a variable reduction in sus-
ceptibility of between 9.1 and 45 times. The viruses which
present this mutation have reduced fitness30.

Enfuvirtide is indicated in HIV+ patients who have
failed with regimens of at least one drug from the three
groups of antiretrovirals or who have developed inter-
ference to previous therapy. Given that the TORO studies
showed a better virological response if enfuvirtide is com-
bined with active drugs, the drug must be administered
before patients have run out of therapeutic options.

T-1249. This is a second-generation fusion inhibitor
It is a 39-aminoacid peptide designed from different
HR-2 regions of HIV-1, HIV-2 and SIV. As with enfuvir-
tide, T-1249 has a high capacity for reducing viral repli-
cation in HIV strains which are multi-resistant to current
drugs, even those which are resistant to T-20, and in sub-
types A to C in naïve patients and those on monother-
apy. T-1249 has proven to be very potent at a single
daily dose (fall in viral load of 2.0 log3,31). Nevertheless, the
clinical development program of this product has been tem-
porarily stopped because of technical difficulties.

The efficacy of enfuvirtide in monotherapy is transito-
ry, therefore it must be combined with other antitretrovi-
rals to which the virus is susceptible. Resistance to enfu-
virtide is related to mutations in the gp41 gene. The
HR-1 and HR-2 domains are relatively stable, but the re-
ported cases of resistance are related to mutations in
codons 36 to 45 of gp41 with a variable reduction in sus-
ceptibility of between 9.1 and 45 times. The viruses which
present this mutation have reduced fitness30.

Enfuvirtide is indicated in HIV+ patients who have
failed with regimens of at least one drug from the three
groups of antiretrovirals or who have developed inter-
ference to previous therapy. Given that the TORO studies
showed a better virological response if enfuvirtide is com-
bined with active drugs, the drug must be administered
before patients have run out of therapeutic options.

T-1249. This is a second-generation fusion inhibitor
It is a 39-aminoacid peptide designed from different
HR-2 regions of HIV-1, HIV-2 and SIV. As with enfuvir-
tide, T-1249 has a high capacity for reducing viral repli-
cation in HIV strains which are multi-resistant to current
drugs, even those which are resistant to T-20, and in sub-
types A to C in naïve patients and those on monother-
apy. T-1249 has proven to be very potent at a single
daily dose (fall in viral load of 2.0 log3,31). Nevertheless, the
clinical development program of this product has been tem-
porarily stopped because of technical difficulties.

The efficacy of enfuvirtide in monotherapy is transito-
ry, therefore it must be combined with other antitretrovi-
rals to which the virus is susceptible. Resistance to enfu-
virtide is related to mutations in the gp41 gene. The
HR-1 and HR-2 domains are relatively stable, but the re-
ported cases of resistance are related to mutations in
codons 36 to 45 of gp41 with a variable reduction in sus-
ceptibility of between 9.1 and 45 times. The viruses which
present this mutation have reduced fitness30.
alytic domain-inhibitor complex, which is giving new life to the study of chemical structures such as diketoacids and tartaric di-cafeoyl acids.

The two most widely studied structures are V-165, which has proven to be potent in vitro and is active against strains resistant to reverse transcriptase and protease inhibitors, and synergetic with some currently marketed antiretrovirals, and S-1300, a diketoacid in phase I studies with very similar tolerance and efficacy characteristics.

Integrase can undergo mutations in its active focus. Nevertheless, the susceptibility of the virus to products currently being studied does not seem to be reduced.

Other possible targets

In addition to the targets mentioned above, we can envisage other possible therapies which are currently a long way off. These involve the mechanisms which condition viral latency, action on genes or the first steps in the synthesis of viral proteins.

One factor which appears to have an influence on the efficacy of viral replication is the glycoprotein APOBEC3G (apolipoprotein B, mRNA editor enzyme, polypeptide-like catalytic 3G, or CEM15). APOBEC3G is an innate intracellular antiretroviral factor which is countered by the lentiviral sf gene protein and which is species-specific. APOBEC3G acts as a cytosine deaminase and, in the viral DNA chain, it changes cytosine for uracil during retrotranscription, thus producing a hypermutation which makes the virus more refractory to further rounds of replication.

Nevertheless, the HIV-1 sf gene is capable of blocking APOBEC3G by avoiding its incorporation into offspring virions, thus facilitating its degradation in the proteasome.

New drugs with action against known targets

The search for new drugs aims to increase potency, modify resistance profiles, reduce toxicity and simplify administration. Drugs with these characteristics which can soon form part of the armamentarium are the nucleoside analog (NA) emtricitabine, the non-nucleoside analog (NN) capravirine and the protease inhibitors (PI) atazanavir, fosamprenavir and tipranavir.

Emtricitabine ( FTC) is a cytidine analog which is administered once daily (200 mg). Its resistance profile is similar to that of lamivudine, but its tolerance is 4-10 times higher, with the result that the mutation M184V, which generates high-grade resistance, appears less frequently. This drug is already available in some countries, given that it displays similar or greater efficacy to lamivudine and stavudine, and its minimal mitochondrial toxicity make it ideal for combining with tenofovir.

Amodoxovir (IAPD) is a guanosine analog with activity similar to that of ABC, 3TC or d4T and an antiviral effect against the hepatitis B virus. It is active against strains which are resistant to ZDV, 3TC, ddI, dDC and ABC. Phase I/II studies are currently being carried out among experienced patients, although its future remains unclear as development has been stopped temporarily.

Capravirine is a potent NN against viral strains resistant to other NNs. At least two simultaneous mutations (L100I, K103N, V106A) are necessary for resistance to appear. It is currently undergoing Phase II testing in NN-experienced patients.

TMC-125 is a new NN which, in vitro, shows equal potency in HIV wild-type and HIV strains which are multi-resistant to NNs (strains with the mutations L100I, K103N, Y181C, Y188L and G190A). In phase II studies of patients with at least two resistance mutations to NVP and EFV, an acceptable response and good tolerance have been observed.

Atazanavir is a protease-inhibiting azapeptide whose pharmacokinetics allows the drug to be administered once daily (200 mg). With this formulation, the number of tablets to be taken is reduced as well as being administered in a single dose, it requires fewer tablets than other drugs (two per day, or three if boosted with ritonavir). It has shown a potency similar to that of efavirenz and in naive patients in their first failure with PI, it has proven to be not inferior to lopinavir/ritonavir (in this case, atazanavir was boosted with ritonavir) at one year of treatment, although the number of mutations to PI at the beginning of the study is unknown. It presents a favorable safety profile, and does not alter either plasma lipids or hypercarbone metabolism, although it does produce indirect hyperbilirubinemia in 10-33% of patients. Furthermore, the resistance profile of ATV seems to be totally different from that of other PI. Mutation E50L, which is specific for resistance to ATV, is different to the E50V observed in patients treated against viral strains which are resistant to currently marketed products.

ATV has shown a potency similar to that of efavirenz and in naive patients in their first failure with PI, it has proven to be not inferior to lopinavir/ritonavir (in this case, atazanavir was boosted with ritonavir) at one year of treatment, although the number of mutations to PI at the beginning of the study is unknown. It presents a favorable safety profile, and does not alter either plasma lipids or hypercarbone metabolism, although it does produce indirect hyperbilirubinemia in 10-33% of patients. Furthermore, the resistance profile of ATV seems to be totally different from that of other PI. Mutation E50L, which is specific for resistance to ATV, is different to the E50V observed in patients treated against viral strains which are resistant to currently marketed products.

TMC-114 is a new PI which has shown activity in vitro against viral strains which are resistant to current PI. In patients presenting their first failure with PI who were randomized to receive NA with tipranavir (500 or 1200 mg)/ritonavir (100 mg) or saquinavir (400 mg)/ritonavir (400 mg)/BID, the fall in VL was 1.4 and 1.8 log at 16 weeks. In patients presenting their second failure to PI treated with tipranavir (500 or 1000 mg)/ritonavir (100 mg) every 12 hours, the fall in viral load at 48 weeks was 2.4 log in the group with five or fewer PI mutations, and 2.5 log in the group with more than five mutations.

TMC-114 is a non-peptidic PI in the early stages of investigation. In vitro, it has been highly active against viral strains with high-level resistance to current PIs. In healthy volunteers, doses over 100 mg have been shown to reach blood levels equivalent to the CI50 of multi-resistant strains. It can be pharmacokinetically boosted with ritonavir and its most marked adverse effects are gastro-intestinal, headache or dizziness.
References

López-Aldeguer, J. et al. New targets and new drugs in the treatment of HIV


